GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (NAS:NEUP) » Definitions » EV-to-FCF

NEUP (Neuphoria Therapeutics) EV-to-FCF : -1.52 (As of Mar. 16, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Neuphoria Therapeutics's Enterprise Value is $11.83 Mil. Neuphoria Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-7.79 Mil. Therefore, Neuphoria Therapeutics's EV-to-FCF for today is -1.52.

The historical rank and industry rank for Neuphoria Therapeutics's EV-to-FCF or its related term are showing as below:

NEUP' s EV-to-FCF Range Over the Past 10 Years
Min: -1.52   Med: -0.28   Max: -0.07
Current: -1.52

During the past 13 years, the highest EV-to-FCF of Neuphoria Therapeutics was -0.07. The lowest was -1.52. And the median was -0.28.

NEUP's EV-to-FCF is ranked worse than
100% of 418 companies
in the Biotechnology industry
Industry Median: 3.79 vs NEUP: -1.52

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-16), Neuphoria Therapeutics's stock price is $4.72. Neuphoria Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.233. Therefore, Neuphoria Therapeutics's PE Ratio (TTM) for today is At Loss.


Neuphoria Therapeutics EV-to-FCF Historical Data

The historical data trend for Neuphoria Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics EV-to-FCF Chart

Neuphoria Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -7,583.11 -2,648.10 -123.74

Neuphoria Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,653.60 -1,913.63 -123.74 -162.54 -0.19

Competitive Comparison of Neuphoria Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Neuphoria Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuphoria Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's EV-to-FCF falls into.



Neuphoria Therapeutics EV-to-FCF Calculation

Neuphoria Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11.829/-7.791
=-1.52

Neuphoria Therapeutics's current Enterprise Value is $11.83 Mil.
Neuphoria Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuphoria Therapeutics  (NAS:NEUP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Neuphoria Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.72/-1.233
=At Loss

Neuphoria Therapeutics's share price for today is $4.72.
Neuphoria Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.233.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Neuphoria Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Neuphoria Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuphoria Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
100 Summit Dr, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.